Clinical Trial: NCT05169567
Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 3| Lead Sponsor: | Eli Lilly and Company |
| Information Provided By: | Eli Lilly and Company |
| Last Update Posted: | 2026-10-06 |
Study Overview
Brief Summary
This study will evaluate the effect of adding abemaciclib to fulvestrant for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that progressed or recurred after previous treatment with a type of drug known as a CDK4/6 inhibitor and endocrine therapy. Participation could last up to 5 years, depending on how you and your tumor respond.
Official Title
Conditions
Intervention / Treatment
- Drug: Abemaciclib
- Drug: Fulvestrant
- Drug: Placebo
Other Study ID Numbers
- 18238
- I3Y-MC-JPEF
- 2021-002301-10
- 2023-506771-10-00
- 2023
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Estimated)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | Eli Lilly and Company |
| Information Provided By: | Eli Lilly and Company |
| Last Update Posted: | 2026-10-06 |
Study Overview
Brief Summary
This study will evaluate the effect of adding abemaciclib to fulvestrant for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that progressed or recurred after previous treatment with a type of drug known as a CDK4/6 inhibitor and endocrine therapy. Participation could last up to 5 years, depending on how you and your tumor respond.
Official Title
Conditions
Intervention / Treatment
- Drug: Abemaciclib
- Drug: Fulvestrant
- Drug: Placebo
Other Study ID Numbers
- 18238
- I3Y-MC-JPEF
- 2021-002301-10
- 2023-506771-10-00
- 2023